Zang et al. proved that the decrease in Mcl-1 and the increase in BIM are the key mechanisms by which osimertinib induces the apoptosis of NSCLC cells with EGFR-TKI-sensitive mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.